Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue—
Net Income-$11.35M-$11.35MN/M vs Q2 2023 EPS Diluted-$0.38-$0.38N/M vs Q2 2023 Operating Income-$12,418,000N/M Operating Cash Flowderived-$7,972,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,972,000N/M ended Jun 30, 2024 · filed Aug 5, 2024 · 36 d after period end